Document is current
Any future updates will be listed below
-
Authors
Yogev, Ohad https://orcid.org/0000-0001-8216-6386
Weissbrod, Omer
Battistoni, Giorgia https://orcid.org/0000-0003-1257-9120
Bressan, Dario https://orcid.org/0000-0003-3592-699X
Naamati, Adi https://orcid.org/0000-0001-6989-3634
Falciatori, Ilaria
Berkyurek, Ahmet Can
Rasnic, Roni
Izuagbe, Rhys https://orcid.org/0000-0001-8080-2510
Hosmillo, Myra
Ilan, Shaul
Grossman, Iris
McCormick, Lauren
Honeycutt, Christopher Cole
Johnston, Timothy https://orcid.org/0000-0001-9246-6155
Gagne, Matthew https://orcid.org/0000-0001-5526-6162
Douek, Daniel C https://orcid.org/0000-0001-5575-8634
Goodfellow, Ian https://orcid.org/0000-0002-9483-510X
Hannon, Gregory James https://orcid.org/0000-0003-4021-3898
Erlich, Yaniv
-
Funding
Funding for this research was provided by:
Bill and Melinda Gates Foundation
Wellcome Trust (207498/Z/17/Z)
RCUK | MRC | Medical Research Foundation (MR/W005611/1)
- License Information
-
More Information
Article History
Received: 29 October 2022
Accepted: 13 February 2023
First Online: 16 March 2023
Competing interests
: O.Y., O.W, A.N., I.F., A.C.B, R.R., S.I., I.G. and Y.E. are Eleven Therapeutics employees. G.J.H is the Scientific co-founder and holds equity in Eleven Therapeutics. G.B. and D.B. hold equity in Eleven Therapeutics. I.G. was acting as an adviser in Eleven Therapeutics when this work was performed.
: All in vivo studies were conducted according to NIH regulations and standards on the humane care and use of laboratory animals as well as the Animal Care and Use Committees of the NIH Vaccine Research Centre and BIOQUAL, Inc. (Rockville, Maryland). All studies were conducted at BIOQUAL, Inc.
